Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Core Points - The U.S. CDC's Advisory Committee on Immunization Practices (ACIP) updated its recommendation for Valneva's chikungunya vaccine IXCHIQ®, maintaining its use for travelers aged ≥18 to chikungunya outbreak areas and considering it for those in elevated risk areas for extended stays [1][2] - ACIP recommended a precaution for IXCHIQ® use in individuals aged ≥65 due to ongoing investigations of serious adverse events (SAEs) reported in older vaccinated individuals [2][3] - Valneva has supplied approximately 80,000 doses of IXCHIQ® across the U.S., Canada, and Europe, with no new SAEs reported since January 2025, and ongoing safety monitoring has not identified any safety signal concerns inconsistent with the U.S. product label [5] Company Overview - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases, including the world's first chikungunya vaccine [9][10] - The company has a strong track record in advancing vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [10][11] - Revenues from Valneva's commercial business support the advancement of its vaccine pipeline, which includes candidates for Lyme disease, Shigella, Zika virus, and other public health threats [11] Industry Context - Chikungunya virus (CHIKV) is a mosquito-borne disease causing significant health issues, with over 3.7 million cases reported in the Americas between 2013 and 2023 [7][8] - The World Health Organization (WHO) has identified chikungunya as a major public health problem, with the disease's economic impact expected to grow due to climate change [8]